Mastek Limited — Updates, 18-04-2025: Press Release

Q4FY25 results show Mastek achieving a revenue of ₹905.4 crore, reflecting a 16.1% increase year-on-year. Operating EBITDA rose to ₹138.8 crore, up 10.9% YoY, with a margin of 15.3%. The healthcare sector saw a notable growth of 13.1% quarter-on-quarter in USD terms. The company’s annual performance also reported a 13.1% increase in revenue and a 20.9% growth in net profit, capped with a strong cash balance of ₹622.2 crore.

Mastek's 12-month order backlog stood at ₹2,290.9 crore, marking a 7.1% quarter-on-quarter growth. Key wins included strategic contracts with the UK’s Central Government and a Fortune 500 financial services client, underscoring Mastek's expanding footprint in both government and private sectors. The proposed final dividend of ₹16 per share reflects a healthy return to shareholders. Looking ahead, Mastek’s focus on enhancing its Data & AI capabilities positions it well for sustainable growth despite ongoing macroeconomic uncertainties. Investors should watch this company closely as it continues to leverage its strengths in digital transformation.